First-in-class Blenrep Approved by European Commission for Myeloma
The European Commission (EC) has approved Blenrep (belantamab mafodotin), a first-in-class therapy developed by GlaxoSmithKline (GSK) for the treatment of multiple myeloma. The approval covers Blenrep as a monotherapy — that is, without other treatments — in adults who have been treated with at least four…